Ask around St. Peters about paying for a newer depression treatment and you will hear confident advice from both camps. Some people swear by fighting for insurance. Others say to skip it and just pay. Both camps tend to carry a few beliefs that do not hold up once you look closely.
We checked six of them against our own ten-state Midwest poll of 443 adults and against how the approved treatment actually works. Those poll numbers are final.
First, where people landed
We asked respondents to choose between a treatment covered by insurance with more hoops and one they would pay for themselves with a simpler process. Just over half chose the covered route. Nearly a quarter chose to pay. Slightly more did not know. Keep that three-way split in mind as you read, because each myth below tends to push people toward one camp without the full picture.
Myth one: "If insurance covers it, it is free."
The reality: Coverage usually means you pay less, not nothing. Depending on your plan, you may owe a copay, coinsurance, or deductible for each session. For esketamine, the spray the FDA approved once usual depression care has failed, the drug itself may bill through either the medical or the pharmacy side of your plan, while the observation visit after each dose bills on its own. Brain Recovery Centers has an overview of esketamine costs and insurance coverage that walks through these pieces. Two people with the same treatment and different plans can see very different bills.
What to do: Before starting, ask the clinic's billing staff for an estimate of your cost per session under your specific plan.
Myth two: "Once insurance says no, that is the end."
The reality: A first denial is often a documentation problem, not a final verdict. Plans typically want a record of the antidepressants you have tried, at what dose and for how long, along with symptom scores. When something is missing, the request can be denied even if you qualify.
What to do: Ask the treating clinic about an appeal or a peer-to-peer review between their prescriber and the insurer's physician. Ask your primary doctor for any records that were missing. Keep a log of every call.
Myth three: "Once you are approved, you are set."
The reality: Many plans approve a treatment for a defined period, then ask for evidence it is working before approving more. That usually means symptom questionnaires along the way.
What to do: Keep your appointments and fill out questionnaires honestly. If the treatment is not helping, that is important information for you and your clinician, not just the insurer.
Myth four: "Paying yourself gets you the same treatment, just faster."
The reality: Often it gets you a different treatment. Plenty of cash-pay clinics sell IV ketamine infusions, an off-label use when the target is depression. Some online services prescribe ketamine for use at home, with much less supervision. Esketamine, by contrast, is FDA-approved and given only at certified sites where you are monitored after each dose.
That difference mattered to our respondents, 59 percent of whom counted FDA approval as a big or deciding reason to try, or skip, a treatment like this. If approval matters to you too, ask any self-pay clinic exactly what it is offering.
What to do: Ask, "Is this esketamine, IV ketamine, or an at-home product? Is it FDA-approved for my condition?"
Myth five: "If you are not sure which route to take, you are not ready."
The reality: Uncertainty is common and reasonable. Just over a quarter of our respondents said they were not sure which route they would choose. Most people have never had to think about this, and 73 percent of respondents had never even heard of Spravato. Being unsure usually means you need information, not that you should wait.
What to do: Take the step most people would take first; 56 percent of respondents would start with their primary doctor. A single appointment and a single call to your insurer can turn uncertainty into a real choice.
Myth six: "The hoops only slow you down. They add nothing."
The reality: Some hoops are frustrating, but several do real work. The medication history your insurer asks for is the same information a clinician needs to judge whether your depression is treatment-resistant. The psychiatric evaluation checks things like blood pressure and health history that affect whether the treatment is safe for you. The certified setting exists because esketamine can cause dissociation, sedation, and blood pressure spikes that need to be watched.
People seem to sense this. In our survey, coverage was a top-two consideration in choosing a provider for 85 percent of respondents, while fast results made the top two for only 24 percent. Most would rather get it right than get it fast.
What to do: Treat the paperwork as part of your care, not a barrier to it. Start the medication history now.
A St. Peters note on distance
Whichever route you choose, clinic-based treatment means you will not be driving yourself home. Early esketamine treatment involves frequent sessions, and certified sites may sit in St. Charles County or over the river in St. Louis County. Our respondents cared about that; a provider close by made the short list for 43 percent. Factor the drive, and the driver, into your decision.
What these myths have in common
Each one simplifies a choice that has real tradeoffs on both sides. The covered route costs time and paperwork but usually offers lower ongoing costs and standardized oversight. The self-pay route can move faster but may mean a different, less regulated treatment and bills that add up over months. Neither is automatically right.
Nothing here is medical or financial advice. The approved use of esketamine is depression that has resisted treatment, and every dose happens under supervision at a certified clinic. A clinician decides whether any treatment fits you.
If depression has you thinking about ending your life, no insurance decision should come first. Dial or text 988. There is no fee, the conversation stays private, and a Lifeline volunteer or staffer (it is the Suicide and Crisis Lifeline) picks up whatever the hour in St. Peters.
Methodology
Pollfish placed survey 395586438 with its consumer panel and stopped fieldwork on June 23, 2026. The count is 443 completes from adults 18 to 64, residents of Missouri, Oklahoma, Kansas, Illinois, Ohio, Wisconsin, Iowa, Indiana, Nebraska and Minnesota. Every figure covers the full sample and is final. Sponsorship and payment both came from the publisher.